Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Alzheimer’s disease beyond amyloid: Can the repetitive failures of amyloid-targeted therapeutics inform future approaches to dementia drug discovery?
Kevin Mullane, Michael Williams
Biochemical Pharmacology (2020) Vol. 177, pp. 113945-113945
Closed Access | Times Cited: 84

Showing 1-25 of 84 citing articles:

The Potential Role of Gut Microbiota in Alzheimer’s Disease: From Diagnosis to Treatment
Angelica Varesi, Elisa Pierella, Marcello Romeo, et al.
Nutrients (2022) Vol. 14, Iss. 3, pp. 668-668
Open Access | Times Cited: 161
The amyloid cascade hypothesis: an updated critical review
Kasper P. Kepp, Nikolaos K. Robakis, Poul Flemming Høilund‐Carlsen, et al.
Brain (2023) Vol. 146, Iss. 10, pp. 3969-3990
Open Access | Times Cited: 106
Aducanumab Therapy to Treat Alzheimer’s Disease: A Narrative Review
Semira Abdi Beshir, Aadith Soorya, Affana Parveen, et al.
International Journal of Alzheimer s Disease (2022) Vol. 2022, pp. 1-10
Open Access | Times Cited: 82
Blood-Based Biomarkers for Alzheimer’s Disease Diagnosis and Progression: An Overview
Angelica Varesi, Adelaide Carrara, Vitor Gomes Pires, et al.
Cells (2022) Vol. 11, Iss. 8, pp. 1367-1367
Open Access | Times Cited: 75
New strategies of neurodegenerative disease treatment with extracellular vesicles (EVs) derived from mesenchymal stem cells (MSCs)
Chella Perumal Palanisamy, Jinjin Pei, Phaniendra Alugoju, et al.
Theranostics (2023) Vol. 13, Iss. 12, pp. 4138-4165
Open Access | Times Cited: 66
Extrasynaptic NMDA receptors in acute and chronic excitotoxicity: implications for preventive treatments of ischemic stroke and late-onset Alzheimer’s disease
Shan Ping Yu, Michael Qize Jiang, Seong S. Shim, et al.
Molecular Neurodegeneration (2023) Vol. 18, Iss. 1
Open Access | Times Cited: 54
The prevalence, correlation, and co-occurrence of neuropathology in old age: harmonisation of 12 measures across six community-based autopsy studies of dementia
Emma Nichols, Richard L. Merrick, Simon I Hay, et al.
The Lancet Healthy Longevity (2023) Vol. 4, Iss. 3, pp. e115-e125
Open Access | Times Cited: 44
DeepDrug as an expert guided and AI driven drug repurposing methodology for selecting the lead combination of drugs for Alzheimer’s disease
Victor O. K. Li, Yang Han, Tushar Kaistha, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access | Times Cited: 2
Copper Toxicity Links to Pathogenesis of Alzheimer’s Disease and Therapeutics Approaches
Hafza Wajeeha Ejaz, Wei Wang, Minglin Lang
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 20, pp. 7660-7660
Open Access | Times Cited: 107
Targeting brain Renin-Angiotensin System for the prevention and treatment of Alzheimer’s disease: Past, present and future
Filipa Gouveia, Antoni Camins, Miren Ettcheto, et al.
Ageing Research Reviews (2022) Vol. 77, pp. 101612-101612
Open Access | Times Cited: 53
Antibody-Mediated Clearance of Brain Amyloid-β: Mechanisms of Action, Effects of Natural and Monoclonal Anti-Aβ Antibodies, and Downstream Effects
David A. Loeffler
Journal of Alzheimer s Disease Reports (2023) Vol. 7, Iss. 1, pp. 873-899
Open Access | Times Cited: 34
Gut-brain axis through the lens of gut microbiota and their relationships with Alzheimer's disease pathology: Review and recommendations
L. Krishaa, Ted Kheng Siang Ng, Hai Ning Wee, et al.
Mechanisms of Ageing and Development (2023) Vol. 211, pp. 111787-111787
Open Access | Times Cited: 30
Alzheimer’s Amyloid Hypothesis and Antibody Therapy: Melting Glaciers?
Poul Flemming Høilund‐Carlsen, Abass Alavi, Rudolph J. Castellani, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 7, pp. 3892-3892
Open Access | Times Cited: 14
Controversial Past, Splendid Present, Unpredictable Future: A Brief Review of Alzheimer Disease History
Félix Bermejo‐Pareja, Teodoro del Ser
Journal of Clinical Medicine (2024) Vol. 13, Iss. 2, pp. 536-536
Open Access | Times Cited: 10
Progress toward Alzheimer's disease treatment: Leveraging the Achilles' heel of Aβ oligomers?
Jacques Fantini, Henri Chahinian, Nouara Yahi
Protein Science (2020) Vol. 29, Iss. 8, pp. 1748-1759
Open Access | Times Cited: 53
The Aβ(1–38) peptide is a negative regulator of the Aβ(1–42) peptide implicated in Alzheimer disease progression
Maa O. Quartey, Jennifer N. K. Nyarko, Jason Maley, et al.
Scientific Reports (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 41
Soluble Amyloid-β Consumption in Alzheimer’s Disease
Alberto J. Espay, Andrea Sturchio, Lon S. Schneider, et al.
Journal of Alzheimer s Disease (2021) Vol. 82, Iss. 4, pp. 1403-1415
Closed Access | Times Cited: 41
Drug Discovery and Development Targeting Dementia
Agnieszka Zagórska, Anna Czopek, Monika Fryc, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 2, pp. 151-151
Open Access | Times Cited: 20
New Drug Discovery
Bancha Yingngam
Advances in medical diagnosis, treatment, and care (AMDTC) book series (2023), pp. 134-184
Closed Access | Times Cited: 19
Gut instincts: Unveiling the connection between gut microbiota and Alzheimer's disease
Vasu Peddinti, Manoj Mohan Avaghade, Sunil Suthar, et al.
Clinical Nutrition ESPEN (2024) Vol. 60, pp. 266-280
Closed Access | Times Cited: 7
Role of Hypoxia Inducible Factor-1α in Alzheimer’s Disease
Yangyang Wang, Zhenting Huang, Minghao Yuan, et al.
Journal of Alzheimer s Disease (2021) Vol. 80, Iss. 3, pp. 949-961
Closed Access | Times Cited: 38
Mitochondrial Dysfunction in Alzheimer’s Disease: Opportunities for Drug Development
Shiveena Bhatia, Rishi Rawal, Pratibha Sharma, et al.
Current Neuropharmacology (2021) Vol. 20, Iss. 4, pp. 675-692
Open Access | Times Cited: 35
Characterising Alzheimer's disease through integrative NMR- and LC-MS-based metabolomics
Jonas Ellegaard Nielsen, Raluca Maltesen, Jesper F. Havelund, et al.
Metabolism Open (2021) Vol. 12, pp. 100125-100125
Open Access | Times Cited: 34
The potential of the gut microbiome for identifying Alzheimer’s disease diagnostic biomarkers and future therapies
Yu Zhan, Murad Al‐Nusaif, Cong Ding, et al.
Frontiers in Neuroscience (2023) Vol. 17
Open Access | Times Cited: 15
The need for systems thinking to advance Alzheimer's disease research
Jeroen F. Uleman, Rick Quax, René J. F. Melis, et al.
Psychiatry Research (2024) Vol. 333, pp. 115741-115741
Open Access | Times Cited: 5
Page 1 - Next Page

Scroll to top